SML2425
Manidipine hydrochloride
≥98% (HPLC)
别名:
1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid hydrchloride, 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl ester, 3-(2-(4-Benzhydrylpiperazin-1-yl)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrchloride, CV 4093 hydrchloride, CV-4093 hydrchloride, CV4093 hydrchloride, Franidipine hydrchloride, Manidipine 6300 hydrchloride
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C35H38N4O6 · xHCl
CAS号:
分子量:
610.70 (free base basis)
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77
推荐产品
化驗
≥98% (HPLC)
形狀
powder
儲存條件
desiccated
顏色
white to beige
溶解度
DMSO: 2 mg/mL, clear (warmed)
儲存溫度
2-8°C
生化／生理作用
Manidipine is a dihydropyridine class calcium channel blocker (CCB) that exerits its antihypertensive activity via targeting both L-type and T-type calcium channels. In contrary to other dihydropyridines and non-dihydropyridines that mainly act as L-type CCBs, Manidipine diminishes glomerular pressure and, consequently, albumin excretion via its action against T-type channels of efferent arterioles in addition to promoting afferent arteriole dilation by blocking L-type channels. Clinically, Manidipine is as effective in lowering blood pressure as other dihydropyridines, while only Manidipine significantly reduces albuminuria and insulin resistance with less adverse effects. In obese and hypertensive individuals, Manidipine is more effective than Lercanidipine in reducing insulin resistance, while Nifedipine treatment is reported to increase insulin desensitisation.
訊號詞
Danger
危險聲明
危險分類
Acute Tox. 3 Oral - STOT SE 3
標靶器官
Central nervous system
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Margarita Saiz-Satjes et al.
Future cardiology, 13(2), 143-151 (2016-11-26)
In AMANDHA trial, the addition of manidipine, but not amlodipine, in diabetic patients with uncontrolled hypertension, microalbuminuria and preserved renal function resulted in a large decrease of urinary albumin excretion (UAE) despite similar blood pressure (BP) reductions. Factors associated with
H Nakaya et al.
European journal of pharmacology, 146(1), 35-43 (1988-01-27)
The effects of CV-4093, a new dihydropyridine derivative, on isolated cardiovascular tissues were compared with those of several dihydropyridine and non-dihydropyridine calcium antagonists. CV-4093 effectively inhibited the contractions induced in canine femoral arteries by high [K+]0 and Bay K 8644
K Okabe et al.
The Journal of pharmacology and experimental therapeutics, 243(2), 703-710 (1987-11-01)
Effects of CV-4093, a newly synthesized dihydropiridine type of Ca antagonist, on membrane currents in enzymatically dispersed single smooth muscle cells of the rabbit main pulmonary artery were investigated using the single electrode voltage clamp method. Three types of membrane
N Buset Ríos et al.
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 31(3), 268-274 (2011-03-17)
The combination of renin-angiotensin system blockers with calcium channel blockers appears to be one of the most effective options for treating hypertension and diabetes.Nevertheless, not all calcium blockers behave in the same manner. Manidipine, unlike other third-generation dihydropyridine derived drugs
Christian Ott et al.
British journal of clinical pharmacology, 75(1), 129-135 (2012-12-18)
Intraglomerular pressure is one of the main drivers of progression of renal failure. Experimental data suggest that there are important differences between calcium channel blockers (CCBs) in their renal haemodynamic effects: manidipine reduces, whereas amlodipine increases intraglomerular pressure. The aim
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门